Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hofer

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|November 16, 2018
High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitisMichael Eder, Robert Strassl, Sandra Beinhardt, et al.
Hepatology (Baltimore, Md.)|September 21, 2011
Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?Sandra Beinhardt, Albert F Staettermayer, Karoline Rutter, et al.
Journal of Hepatology|April 20, 2010
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapyHarald Hofer, Josef Donnerer, Kathrin Sator, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 10, 2015
Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathyLukas Weseslindtner, Iris Macheleidt, Hannah Eischeid, et al.
Experimental Cell Research|May 25, 2002
Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3)Petra Bareis, Enikö Kállay, Martin G Bischof, et al.
Wiener Klinische Wochenschrift|September 15, 2020
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Emina Halilbasic, Harald Hofer, et al.
Wiener Klinische Wochenschrift|October 9, 2004
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadineRudolf E Stauber, Harald Hofer, Franz Hackl, et al.
The American Journal of Gastroenterology|November 12, 2002
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3aHarald Hofer, Hans C Bankl, Friedrich Wrba, et al.
Gastroenterology|September 6, 2008
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapyPeter Ferenci, Thomas-Matthias Scherzer, Heidrun Kerschner, et al.
Journal of Hepatology|May 12, 2005
Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosisChristoph H Osterreicher, Christian Datz, Felix Stickel, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Liver International : Official Journal of the International Association for the Study of the Liver|November 16, 2018
High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitisMichael Eder, Robert Strassl, Sandra Beinhardt, et al.
Hepatology (Baltimore, Md.)|September 21, 2011
Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?Sandra Beinhardt, Albert F Staettermayer, Karoline Rutter, et al.
Journal of Hepatology|April 20, 2010
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapyHarald Hofer, Josef Donnerer, Kathrin Sator, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 10, 2015
Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathyLukas Weseslindtner, Iris Macheleidt, Hannah Eischeid, et al.
Experimental Cell Research|May 25, 2002
Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3)Petra Bareis, Enikö Kállay, Martin G Bischof, et al.
Wiener Klinische Wochenschrift|September 15, 2020
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Emina Halilbasic, Harald Hofer, et al.
Wiener Klinische Wochenschrift|October 9, 2004
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadineRudolf E Stauber, Harald Hofer, Franz Hackl, et al.
The American Journal of Gastroenterology|November 12, 2002
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3aHarald Hofer, Hans C Bankl, Friedrich Wrba, et al.
Gastroenterology|September 6, 2008
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapyPeter Ferenci, Thomas-Matthias Scherzer, Heidrun Kerschner, et al.
Journal of Hepatology|May 12, 2005
Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosisChristoph H Osterreicher, Christian Datz, Felix Stickel, et al.
Pageof 8